Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells

Citations of this article
Mendeley users who have this article in their library.


<p> Ischemic diseases are a group of diseases, including ischemic cerebrovascular disease, ischemic cardiomyopathy (ICM), and diabetic foot as well as other diseases which are becoming a leading cause of morbidity and mortality in the whole world. Mesenchymal stem cells (MSCs) have been used to treat a variety of ischemic diseases in animal models and clinical trials. Lots of recent publications demonstrated that MSCs therapy was safe and relieved symptoms in patients of ischemic disease. However, many factors could influence therapeutic efficacy including route of delivery, MSCs’ survival and residential rate <italic>in vivo</italic> , timing of transplantation, particular microenvironment, and patient’s clinical condition. In this review, the current status, therapeutic potential, and the detailed factors of MSCs-based therapeutics for ischemic cerebrovascular disease, ICM, and diabetic foot are presented and discussed. We think that MSCs transplantation would constitute an ideal option for patients with ischemic diseases. </p>




Li, S., Wang, X., Li, J., Zhang, J., Zhang, F., Hu, J., … Li, Q. (2016). Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells. Stem Cells International. Hindawi Limited.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free